Forbes Community GuidelinesOur community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.In order to do so, please follow the posting rules in our site's Terms of Service.  We've summarized some of those key rules below. Simply put, keep it civil.Your post will be rejected if we notice that it seems to contain:False or intentionally out-of-context or misleading informationSpamInsults, profanity, incoh ...

In this articleAZN-GBBMYLLYNVSNOV.N-CHSkynesher | E+ | Getty ImagesBig pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a "massive opportunity."It's called targeted radiopharmaceuticals. The therapy essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.RBC Capital Markets sees a $25 billion market opportunity for the space."We believe TRT development is still in its early stages, and next- ...

This top pharma stock has fallen too far.Dividend stocks are an important anchor for well-balanced portfolios. Regular cash distributions can buffer a portfolio against market volatility and provide a steady income across business cycles.Still, picking dividend stocks is no easy task. Companies operating in high-tech areas like healthcare often face unique competitive pressures that can diminish free cash flows, lowering their ability to reward shareholders via ever-larger dividend checks. Bristol Myers Squ ...

Bristol Myers Squibb (BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024.The subcutaneous formulation of Opdivo is co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20). The BLA seeks approval of the same across all previously approved adult, solid tumor indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or i ...

Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selectionLONDON, May 22, 2024 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round.The additional investment from Bristol Myers Squibb will enable NeoPhore to explore novel biology associated with the DNA mismatch repair ('MMR' ...

Key PointsPerspective Therapeutics' major shareholder doubled down on the position, validating the business and pipeline. Liberty Live Group's SiriusXM stock is bought by Warren Buffett and Berkshire Hathaway. NB Bancorp is an aged institution that recently IPOd with great success; it is still undervalued. The threat of fines and imprisonment, up to twenty years for the worst offenders, makes insider trading a different game than what it was. Today, insiders must reveal their trading within days of executio ...

Bristol Myers Squibb (BMY) announced that the FDA has granted accelerated approval to the label expansion of chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel).The regulatory body approved Breyanzi for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approv ...

Bristol-Myers Squibb Company (NYSE:BMY) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham – Bank of America Chen Yang – Bank of America Geoff Meacham I’m Geoff Meacham. I’m the senior biopharma analyst, and I have Charlie from my team on stage with me as well. Welcome to the Bristol-Myers session. So on behalf of Bristol, we have CFO, David Elkins. David ...

Bristol-Myers Squibb Company (NYSE:BMY) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham – Bank of America Chen Yang – Bank of America Geoff Meacham I’m Geoff Meacham. I’m the senior biopharma analyst, and I have Charlie from my team on stage with me as well. Welcome to the Bristol-Myers session. So on behalf of Bristol, we have CFO, David Elkins. David ...

Give someone a dividend and you pay them that day but teach them to capture the dividend and you provide investment income for life!Executing a capture-the-dividend trade entails buying the stock before the ex-date so you are the shareholder of record. You then sell it to book the dividend income, making little if any capital gains (that would be nice but it is not the objective). There are many factors to consider in buying dividend stocks for tactical traders.  The bigger the dividend the bigger the profi ...